

Jianzhong Wang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3999370/publications.pdf>

Version: 2024-02-01

34
papers

402
citations

840585

11
h-index

839398

18
g-index

35
all docs

35
docs citations

35
times ranked

311
citing authors

#	ARTICLE	IF	CITATIONS
1	African swine fever virus MGF360-11L negatively regulates cGAS-STING-mediated inhibition of type I interferon production. <i>Veterinary Research</i> , 2022, 53, 7.	1.1	40
2	Evaluation of dermal irritation and skin sensitization due to vitacoxib. <i>Toxicology Reports</i> , 2017, 4, 287-290.	1.6	39
3	African swine fever virus MGF505-11R inhibits type I interferon production by negatively regulating the cGAS-STING-mediated signaling pathway. <i>Veterinary Microbiology</i> , 2021, 263, 109265.	0.8	37
4	Development of a reverse genetics system based on RNA polymerase II for Newcastle disease virus genotype VII. <i>Virus Genes</i> , 2015, 50, 152-155.	0.7	26
5	Nonlinear mixed-effects pharmacokinetic modeling of the novel COX-2 selective inhibitor vitacoxib in dogs. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2019, 42, 530-540.	0.6	26
6	Generation and evaluation of a recombinant genotype VII Newcastle disease virus expressing VP3 protein of Goose parvovirus as a bivalent vaccine in goslings. <i>Virus Research</i> , 2015, 203, 77-83.	1.1	24
7	Safety assessment of vitacoxib: Acute and 90-day sub-chronic oral toxicity studies. <i>Regulatory Toxicology and Pharmacology</i> , 2017, 86, 49-58.	1.3	21
8	Determination of vitacoxib, a novel COX-2 inhibitor, in equine plasma using UPLC-MS/MS detection: Development and validation of new methodology. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2017, 1061-1062, 270-274.	1.2	20
9	Pharmacokinetic Modeling of Ceftiofur Sodium Using Non-linear Mixed-Effects in Healthy Beagle Dogs. <i>Frontiers in Veterinary Science</i> , 2019, 6, 363.	0.9	18
10	Construction and evaluation of recombinant <i>Lactobacillus plantarum</i> NC8 delivering one single or two copies of G protein fused with a DC-targeting peptide (DCpep) as novel oral rabies vaccine. <i>Veterinary Microbiology</i> , 2020, 251, 108906.	0.8	18
11	Network pharmacology-based study on the mechanism of scutellarin against zearalenone-induced ovarian granulosa cell injury. <i>Ecotoxicology and Environmental Safety</i> , 2021, 227, 112865.	2.9	12
12	Acute, mutagenicity, teratogenicity and subchronic oral toxicity studies of diaveridine in rodents. <i>Environmental Toxicology and Pharmacology</i> , 2015, 40, 660-670.	2.0	11
13	An inactivated recombinant rabies virus displaying the Zika virus prM-E induces protective immunity against both pathogens. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009484.	1.3	10
14	Safety assessment of vitacoxib: 180-day chronic oral toxicity studies. <i>Regulatory Toxicology and Pharmacology</i> , 2018, 95, 244-249.	1.3	9
15	Evaluation of pharmacokinetic properties of vitacoxib in fasted and fed horses. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2018, 41, 843-847.	0.6	8
16	A bacterium-like particle vaccine displaying Zika virus prM-E induces systemic immune responses in mice. <i>Transboundary and Emerging Diseases</i> , 2022, 69, .	1.3	8
17	Mutagenicity and teratogenicity studies of vitacoxib in rats and mice. <i>Toxicology Reports</i> , 2018, 5, 827-831.	1.6	7
18	Pharmacokinetics of altrenogest in gilts. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2019, 42, 660-664.	0.6	7

#	ARTICLE	IF	CITATIONS
19	Development of an enzyme-linked immunosorbent assay for the detection of mebendazole in chicken and mutton. <i>Analytical Methods</i> , 2021, 13, 1740-1746.	1.3	7
20	Multidrug-Resistant <i>Klebsiella pneumoniae</i> Complex From Clinical Dogs and Cats in China: Molecular Characteristics, Phylogroups, and Hypervirulence-Associated Determinants. <i>Frontiers in Veterinary Science</i> , 2022, 9, 816415.	0.9	7
21	Multifunctional TK-VLPs nanocarrier for tumor-targeted delivery. <i>International Journal of Pharmaceutics</i> , 2016, 502, 249-257.	2.6	6
22	Pharmacokinetics of the novel COX-2 selective inhibitor vitacoxib in cats: The effects of feeding and dose. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2019, 42, 294-299.	0.6	6
23	Pharmacokinetics of vitacoxib in rabbits after intravenous and oral administration. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2019, 42, 368-371.	0.6	5
24	A highly efficient recombinant canarypox virus-based vaccine against canine distemper virus constructed using the CRISPR/Cas9 gene editing method. <i>Veterinary Microbiology</i> , 2020, 251, 108920.	0.8	5
25	Adjuvant effects of bacterium-like particles in the intranasal vaccination of chickens against Newcastle disease. <i>Veterinary Microbiology</i> , 2021, 259, 109144.	0.8	5
26	The pharmacokinetics of buserelin after intramuscular administration in pigs and cows. <i>BMC Veterinary Research</i> , 2022, 18, 136.	0.7	4
27	Determination of Lekethromycin, a Novel Macrolide Lactone, in Rat Plasma by UPLC-MS/MS and Its Application to a Pharmacokinetic Study. <i>Molecules</i> , 2020, 25, 4676.	1.7	3
28	Pharmacokinetics of three formulations of vitacoxib in horses. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2020, 43, 364-368.	0.6	3
29	Antitumour metastasis and the antiangiogenic and antitumour effects of a <i>Eimeria stiedae</i> soluble protein. <i>Parasite Immunology</i> , 2021, 43, e12825.	0.7	3
30	Development of recombinase polymerase amplification assays for rapid and visual detection of canine distemper virus infecting giant panda. <i>BMC Veterinary Research</i> , 2021, 17, 172.	0.7	3
31	The pharmacokinetics of moxidectin following intravenous and topical administration to swine. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2019, 42, 111-115.	0.6	2
32	Pharmacokinetics and bioavailability of carbetocin after intravenous and intramuscular administration in cows and gilts. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2020, 43, 237-240.	0.6	1
33	Non-Linear Mixed-Effects Pharmacokinetic Modeling of the Novel COX-2 Selective Inhibitor Vitacoxib in Cats. <i>Frontiers in Veterinary Science</i> , 2020, 7, 554033.	0.9	1
34	Pharmacokinetics, Tissue Distribution, Metabolism and Excretion of a Novel COX-2 Inhibitor, Vitacoxib, in Rats. <i>Frontiers in Veterinary Science</i> , 2022, 9, 884357.	0.9	0